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Leishmaniasis is a group of tropical diseases caused by parasitic protozoa belonging to the genus Leishmania.
The disease is categorized in cutaneous leishmaniasis (CL), mucocutaneous leishmaniasis (MCL), and visceral
leishmaniasis (VL). The conventional treatment is complex and can present high toxicity and therapeutic failures.
Thus, there is a continuing need to develop new treatments. In this review, we focus on the novel molecules
described in the literature with potential leishmanicidal activity, categorizing them in pre-clinical (in vitro, in vivo),
drug repurposing and clinical research.
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1. Introduction
Leishmaniasis is a group of tropical diseases caused by
protozoan parasites belonging to the genus
Leishmania.[1] There are more than 20 species of
Leishmania distributed worldwide and each species
can cause different clinical manifestations, which can
be grouped into three main clinical forms: cutaneous
leishmaniasis (CL), mucocutaneous leishmaniasis (MCL)
and visceral leishmaniasis (VL).[2,3] CL is the most
common form of the disease and it is generally
painless and chronic.[4] In general, the lesions occur at
the sites bitten by the infected sand fly, such as the
face, legs and arms. MCL is characterized by lesions
that can partially or totally destroy the mucous
membranes of the cavities of the nose, mouth and
throat, which can lead to disfigurement of the patient
with consequent social exclusion.[5] VL is the most
serious manifestation of the disease and it is charac-
terized by fever, weight loss, enlargement of liver and
spleen, pancytopenia and hypergammaglobulinemia
and it may be fatal if left untreated.[6,7] Leishmaniasis
predominantly affects the poor population of coun-
tries in Africa, Asia and Latin America. Recent estimates
indicate that about 350 million of people live in a
vulnerable situation with the risk of contracting
leishmaniasis. In a global perspective, the disease
currently affects around 12 million people
worldwide.[8] According to WHO, there are currently
98 countries that are endemic for leishmaniasis; nine
of them are endemic only for VL, 21 only for CL and
68 countries are endemic for both leishmaniasis
forms.[7]
Leishmania spp. are digenetic parasites, presenting
two main evolutionary forms during their life cycle:
promastigote, present in the invertebrate host and
amastigote (present in the vertebrate host). The
promastigote form is transmitted to the vertebrate
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host by the bite of infected female phlebotominae
sandflies. The promastigotes differentiate into amasti-
gotes in the vertebrate’s host, multiply intensely and
spread infection (Figure 1).[9–11]
Currently, chemotherapy is the basis of antileishma-
nial treatment. Different drugs are available for use,
the choice of medication varying according to the
disease form and the geographic region.[12,13] The
available drugs are however not ideal, showing high
toxicity and low efficacy in some endemic regions.[12,14]
Moreover, therapeutic failure, patient recurrence and
deaths due to the disease complications are often
observed, requiring new efficient treatment options
that are less toxic. In this review, we bring together
information regarding new molecules with potential
leishmanicidal activity. We first describe the drugs
currently in use for the treatment of leishmaniasis and
highlight their limitations. Then, we relate the new
molecules with good potential, classifying them
according to the drug development timeline (Figure 2)
into pre-clinical (in vitro, in vivo analysis) and clinical
phase, also including an extra topic on drug repurpos-
ing. Finally, we discuss future perspectives to address
the current limitations.
2. Current Treatment Options and Limitations
The drugs of choice for the treatment of CL and VL are
pentavalent antimonials, commercially available in the
forms of meglumine antimoniate (Glucantime®) or
sodium stibogluconate (Pentostam®).[12] Pentavalent
antimonials are registered and licensed in Southeast
Asia, Latin America and some Mediterranean and
African countries.[12] Although these compounds are
highly effective in different parts of the world, like
Africa, they have been ineffective in India, due to the
emergence of resistant strains.[15] Antimonials have
low cost and can be administered intravenously
(Pentostam) or intramuscularly (Glucantime), and they
have also been applied intralesionally for the treat-
ment of CL.[12,16] Although effective, reports of side
effects are common in therapy with antimonials, such
as nephrotoxicity, cardiotoxicity (arrhythmia, prolonga-
tion of the Q  T interval, ventricular tachycardia),
hepatotoxicity and elevated levels of pancreatic
enzymes.[12,14] HIV-Leishmania co-infection has also
been associated with an increase in the number of
recurrence cases after treatment with antimonials, as
well as with the increase in the number of deaths.[17]
Moreover, treatment with antimonials is long, which,
Figure 1. Life cycle of Leishmania in the invertebrate and vertebrate hosts.
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together with the high toxicity, makes it difficult for
patients to adhere to the treatment.[15]
Other drugs have also been widely used in the
treatment of leishmaniasis, such as amphotericin B
deoxycholate (AmB).[12] AmB is a polyene antifungal
that has been used as alternative drug in the treat-
ment of leishmaniasis caused by antimonial-resistant
strains.[18] Although highly effective, AmB also has a
number of side effects, including nephrotoxicity,
electrolyte abnormalities, hypokalemia and myocardi-
tis, requiring hospitalization of the patient and increas-
ing the cost of treatment.[18] In order to minimize
these toxic effects, lipid formulations of AmB have
been developed, such as liposomal AmB (L-AmB)
(AmBisome®), AmB colloidal dispersion (ABCD) (Am-
phocil®) and AmB lipid complex (ABLC) (Abelcet®).[18,19]
These new formulations are just as effective as the
original AmB, while at the same time showing better
tolerability and less toxicity.[16] Liposomal AmB has
been the drug of choice in the treatment of patients
with HIV co-infection.[20] However, a study in Bihar,
India, showed that the use of this drug in the
treatment of these patients did not show any reduc-
tion in rates of recurrence and mortality compared to
HIV-negative patients.[21] Lipid-based formulations of
AmB are quickly targeted at the organs where the
disease develops, so that other organs, such as the
kidneys, are saved, which reduce their adverse side
effects.[18] However, although AmB liposomal formula-
tions are effective and better tolerated, they still need
to be administered by intravenous infusions, which
require hospitalization of the patient for treatment.
Along with this, the high cost of treatment has
restricted its use in therapy.[22]
Another drug available for the treatment of
leishmaniasis is paromomycin, an aminoglycoside-
aminocyclitol antibiotic, used for the first time in the
treatment of leishmaniasis in 2002, in the form of
paromomycin sulfate.[22] It has been used to treat both
forms of the disease, being used in parenteral
formulations in the treatment of VL and in topical and
parenteral formulations in the treatment of CL.[6] Since
leishmaniasis mainly affects low-income populations,
the low cost is one of the main advantages of
paromomycin, although its parenteral administration
makes it difficult for patients to adhere to
treatment.[18] Paromomycin has high efficacy and
excellent tolerability; however, side effects have also
been reported, such as nephrotoxicity, ototoxicity,
reversible increase in liver transaminases and pain at
the injection site.[11,12] Furthermore, although cases of
resistance have not yet been reported, the develop-
Figure 2. Stages of drug development. The development of a new drug follows several stages such as drug discovery, pre-clinical
development, clinical development, and regulatory approval. Researchers begin the discovery of new drugs with potential for the
treatment of the disease (for example leishmaniasis) and initiate tests in cells and animals. Then, it proceeds to the clinical research
phase with the objective of testing the safety and effectiveness in humans. The development of a new medicine lasts for
approximately 15 years before reaching the consumer market.
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ment of in vitro resistance to paromomycin has already
been reported in some species of Leishmania.[19]
Pentamidine is an aromatic diamidine used as
a second-line medication in the treatment of leishma-
niasis, being administered intramuscularly and its main
advantage is short-term therapy.[14,19] On the other
hand, pentamidine presents serious adverse reactions,
such as nephrotoxicity, cardiotoxicity, pancreatitis,
hypoglycemia, leukopenia and anemia, which require
constant monitoring of the patient.[12] In addition,
compared to other drugs, its effectiveness varies
between Leishmania species, which has led to a
reduction of its use in clinical treatment.[14,19]
Miltefosine is an alkylphosphocholine drug, origi-
nally developed as an anticancer agent, was the first
oral drug approved for the treatment of VL and CL. In
general, it is a well-tolerated drug, but some adverse
effects have already been reported, such as nephrotox-
icity, gastrointestinal toxicity, and occasional liver
toxicity, which makes it necessary to monitor the
patient during treatment. Miltefosine also has terato-
genic effects and abortive properties, which limits its
use during pregnancy; in addition, its high half-life
(about 1 week) can stimulate the development of
resistance.[14,18]
Sitamaquine (8-aminoquinoline) is another medica-
tion that has the advantage of oral administration
route. The main adverse effect observed was neph-
rotoxicity, and other effects were also seen, for
example, vomiting, dyspepsia, glomerulonephritis, and
headache. However, at doses well tolerated by the
body, the drug showed low efficacy. The development
of resistance has not yet been reported, although
promastigote forms of L. donovani resistant to sitama-
quine have been selected in the laboratory.[19]
3. New Molecules with Potential for Treatment
3.1. In Vitro Studies
The efficacy of treatment for leishmaniasis depend on
a number of factors linked to the host, the environ-
ment, the type of drug administered and the
parasite.[23] The scientific community is always search-
ing for new therapeutic strategies, and new low cost,
less toxic and more effective compounds for the
treatment of leishmaniasis. Thus, over the years, new
molecules that inhibit the survival of Leishmania have
been extensively investigated. Initially, to evaluate the
potential of new drugs and their toxicity, laboratory
studies are conducted as in vitro tests. These tests are
generally used to evaluate cell toxicity and viability
and have several advantages such as low cost, limited
toxic waste, and controlled testing conditions.[24,25] In
this topic we describe the novel molecules which have
shown potential antileishmanial effect in the in vitro
tests.
Oliveira et al. reported the use of five thiazole
derivatives of the thiazopyridines class (TP) and five of
the thiazoacetylpyridines class (TAP) to evaluate in vi-
tro activity against L. infantum.[26] Thiazoles are a class
of compounds that exhibit broad range of biological
activity, including antitumor, antibacterial, and anti-
inflammatory activities. In this study, all the tested
compounds inhibited the growth of promastigotes
and presented low cytotoxicity. However, TAP-01, TAP-
04 and TAP-06 presented higher potential with lower
IC50 values against amastigote (0.99, 0.43 and 0.59 μM,
respectively). TAP-04 (Figure 3, Structure 1, S1) showed
better activity against both forms of the parasite, as
well as lower cytotoxicity, and high selectivity index
(SI/amastigote=137.37) which is about seven times
higher than the minimum established for a promising
drug. The authors also investigated the possible intra-
cellular targets, as well as the effect of the compounds
on the parasite’s cell membrane. The promastigotes
without the addition of TAP-04 presented regular
morphology, with a well-preserved nucleus, occupying
the most central part of the cytoplasm, and chromatin
associated with the internal nuclear membrane. After
exposure to 1/2× IC50 TAP-04, the promastigotes
presented swollen mitochondria with intense disorga-
nization in the mitochondrial ridges, in addition to
changes in the shape of the cell body, presenting
rounded morphology and loss of the flagellum,
together with loss of cell volume with intense wrinkles,
suggesting cell death via apoptosis.
Chauhan et al. analyzed the leishmanicidal activity
of trans-dibenzalacetone (DBA, S2), a low cost and
easily synthesizable monoketone analog of
curcumin.[27] The authors observed an IC50 of 7.43�
1.88 μg/mL and 17.80�1.42 μg/mL for amastigotes
and promastigotes, respectively. The treatment of
promastigotes with DBA caused morphological
changes, such as cell reduction and rounding, in
addition to extensive cytoplasmic vacuolization after
24 h of treatment. In addition, features associated with
apoptosis such as cell arrest in the G0/G1 phase,
depolarization of the mitochondrial membrane poten-
tial and an increase in cytosolic Ca2+ levels were
observed. The authors also reported reduced levels of
glutathione (GSH) in the treated cells compared to
untreated cells. Kinetoplastids like Leishmania and
Trypanosoma show an unusual form of glutathione
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Figure 3. Chemical structures of the molecules cited in this work. S1-TAP-04, S2-DBA, S3-chitosan, S4-EAPB0503, S5-Isopentyl
caffeate, S6-ursolic acid, S7-GF1059, S8-Ruthenium nitrosol complex, S9-SB-83, S10-Compound 8, S11-DNDI-6148, S12-DNDI-1044,
S13-DNDI-0690, S14-DNDI-8219, S15-DNDI-VL-2098, S16-DDD853651/GSK3186899, S17-GSK3494245/DDD01305143, S18-Clomipr-
amine, S19-Amiodarone, S20-Fexinidazole, S21-LXE408.
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(trypanothione) essential for the survival of the para-
site and which is the target for the development of
new drugs.
Chitosan (S3) is a biodegradable cationic polysac-
charide, with proven antimicrobial, antileishmanial and
immunostimulating activities.[28] Previous studies have
shown its in vitro antileishmanial activity with IC50
ranging from 70 to 240 μg/mL against both promasti-
gotes and amastigotes forms of L. infantum, L. amazo-
nensis and L. chagasi.[29–31] Recently, Riezk et al. eval-
uated the in vitro antileishmanial activity of various
forms of chitosan, including low, medium and high
molecular weight chitosan and its derivatives, against
extracellular promastigotes and intracellular amasti-
gotes of L. major and L. mexicana.[32] In this study, the
authors demonstrated for the first time a pH depend-
ent antileishmanial activity of chitosan and its deriva-
tives, which may justify the great variability of the
antileishmanial activity of this compound in the
literature. The authors reported minimal cytotoxicity
against human squamous carcinoma cells (KB cells),
with CC50 of 750 μg/mL at pH 7.5 or 6.5. Chitosan and
its derivatives were approximately 7 to 20 times more
active at pH 6.5 than at pH 7.5, with high molecular
weight chitosan being the most potent (except
carboxymethyl chitosan). This increased chitosan activ-
ity at a lower pH of 6.5 may be due to its greater
ionization. It is believed that the positive charge can
increase the antimicrobial activity of chitosan due to
the interaction with the negatively charged microbial
membrane. The authors concluded that chitosan and
its water-soluble derivatives have antileishmanial activ-
ity against L. major and L. mexicana promastigotes and
amastigotes in a pH-dependent manner and that their
antileishmanial activity is related to the direct uptake
of chitosan in the parasitophore vacuole by pinocyto-
sis.
El Hajj et al. characterized the effect of imiquimod,
an immunomodulatory drug, against L. tropica and
L. major, and elucidated the molecular mechanisms
that dictate antileishmanial efficacy against both the
strains.[33] In addition, they also investigated the
potency and molecular mechanisms of an imiquimod
analog, EAPB0503 (S4), against these two strains. Both
drugs reduced the replication of amastigotes, how-
ever, the compound EAPB0503 was more potent,
particularly against amastigote forms of L. tropica. Toll-
like receptor 7 (TLR7) was found to be positively
regulated, mainly by imiquimod, and to a lesser extent
by EAPB0503. Furthermore, the drugs activated the
canonical route of NF-кB, generating an immune
response and the superregulation of i-NOS in infected
macrophages. The authors conclude that imiquimod
and EAPB0503 could be strong candidates for the
treatment of L. tropica.
Our group has been studying isopentyl caffeate
(ICaf, S5) for its antileishmanial activity. ICaf is derived
from caffeic acid and has shown good activity against
the promastigote and amastigote forms of cutaneous
(L. amazonensis) and visceral (L. chagasi)
leishmaniasis.[34,35] The hydrophobic nature of ICaf
limit its bioavailability. To overcome its low solubility
an inclusion complex of ICaf in β-cyclodextrin (β-CD)
was developed. The ICaf/β-CD with improved solubility
retained high antileishmanial activity in vitro (<10 μg/
mL) against both L. amazonensis and L. chagasi.
3.2. In Vivo Studies
The safety assessment of new molecules requires
animal studies before advancing for clinical trials.
These in vivo studies aim to obtain information on
several aspects of the new molecule with respect to its
functioning in a biological system, before its testing in
humans.[36,37] The selection of the animal model to be
used is one of the most important steps, since the
choice of the species will give the best correlation
with the human trials. Differences in the gut, enzyme
activity, circulatory system, or other characteristics
make certain models more suitable than others for a
given goal. For example, differences in metabolism
between two species will affect both toxicology and
efficacy of the substance.[37,38] It is also important to
mention that animal models of human diseases not
only facilitate compound selection and early assess-
ment of the mechanism of action, but also provide a
better understanding of the therapeutic index and
therefore improve clinical-dose selection for human
trials.[39]
Bilbao et al. evaluated the efficacy of ursolic acid
(UA, S6),[40] a multifunctional triterpenoid with proven
antitumor, antioxidant, antimicrobial and antifungal
activities.[41,42] In this study, in vivo UA activity was
evaluated in both acute and chronic models of VL. In
addition, topical formulations were also developed,
and their efficacy was tested in a chronic model of CL.
The authors first reported the antileishmanial activity
in vitro against amastigotes of L. amazonensis and
L. infantum, being six and three times greater than the
promastigotes, respectively. Also, the selectivity index
of UA was found to be higher (three and eight-fold
higher depending on the strain) compared to miltefo-
sine. The authors explained greater activity of UA
observed in the amastigotes compared to the promas-
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tigotes by their dual mode of action. UA showed
activity not only on the parasite, but also stimulated
the immunological response of the host cell, mainly by
increasing NO production in macrophages. In acute
and chronic model of L. infantum (VL), UA was tested
via intraperitoneal route administering 5 mg/kg daily
for seven consecutive days. A 99,83% and 99,78%
reduction in the parasitic load was observed in the
spleen and liver in the acute model, while a 58% and
79% reduction in the number of parasites in the
spleen and liver was observed in the chronic model. In
the chronic model for CL, the lesion progression
decreased by approximately 42% and 50% (at
weeks 10 and 15) during topical administration of AU
ointment (0, 2%) for 28 days. However, it can be noted
that the parasites were not fully eradicated after
topical administration, since inflammation increased at
week 15. AU was shown to modulate the Th1 response
in the immune system, resulting in the death of the
parasite, by increasing of IFN-γ and decreased IL-4.
Furthermore, no evident signs of toxicity were ob-
served in the animals, which suggests that ursolic acid
was well tolerated in the administered dose, making it
a promising candidate against visceral and cutaneous
leishmaniasis.
In 2019, in an in vitro and in vivo study against
L. infantum and L. amazonensis, Soyer et al. evaluated
the activity of a chloroquinoline derivative (GF1059,
S7) by means of cytotoxicity analysis in macrophages,
hemolytic potential in human red blood cells, and
efficacy of the compound against infected
macrophages.[43] The data showed IC50 of 4.23�0.34
and 7.53�1.04 μM against promastigotes, and 4.73�
1.09 and 8.75�1.10 μM against amastigotes of L. in-
fantum and L. amazonensis, respectively. Macrophages
treated with GF1059 prior to infection with L. amazo-
nensis and L. infantum showed 79% and 80% reduced
infection. The authors also reported a reduction in the
parasitic load in infected tissue (50%), spleen (29%),
liver (50%) and lymph node (59%). GF1059 showed
low toxicity and did not induce hemolysis in human
red blood cells. The compound also resulted in
decreased membrane potential, increased autophagic
vacuolos and excessive production of reactive oxygen
species, all of which were probably responsible for
causing death of the parasite. In addition, phosphati-
dylserine markers and membrane integrity were also
evaluated, and, despite mitochondrial damage, the
results did not show any type of alteration in these
evaluations.
Nascimento et al. evaluated the leishmanicidal
potential of the ruthenium nitrosol complex (RuNO,
S8) against L. brasiliensis by means of an in vitro (mice
dermal fibroblasts) and an in vivo study (using
hamsters).[41] The nitrosyl ruthenium complexes have
proven biological activity, such as antiparasitic, anti-
angiogenic, analgesic, gastroprotective and cerebral
neuroprotection.[44–49] In this study, the authors
showed that RuNo had no cytotoxic effect on dermal
fibroblasts at any of the concentrations tested. In the
in vitro tests, 4 h treatment with RuNO complex
(100 μM) could completely reduce the number of
infected cells. Similarly, in the hamster model, after the
first week it was possible to observe a reduction in
lesion size. The number of parasite decreased 99.9%
with 300 μg/kg/day of the compound. Despite good
leishmanicidal action, this study did not report any
possible mechanism of action, however, the authors
discuss that NO is one of the crucial molecules in the
control of the parasitic load during the development
of cutaneous leishmaniasis. Ruthenium complexes
have shown to function as NO donor and associated
with antileishmanial activity by NO release and intra-
cellular elimination of the parasite.[44,50]
Rodrigues et al. analyzed the acute toxicity, geno-
toxicity and oral efficacy of SB-83 (S9) (a 2-amino-
tiophene derivative) in vivo against L. amazonensis.[51]
Thiophene belong to a group of aromatic heterocyclic
compounds and present biological properties such as
anti-inflammatory, antitumor, antinociceptive, anticon-
vulsant and antiarrhythmic activities.[52] The authors
demonstrated that in the ninth week of the treatment
with SB-83 (200 mg/kg), there was a reduction in
lesion size by 52.47%�5.32. The parasitic load was
reduced in the lymph node (42.57%�3.14) and in the
spleen (100%). Th1 and Th2 responses were analyzed
by measuring IFN-γ and IL-10 levels, respectively. An
increase in IFN-γ (5.67 times) was observed without
any alteration in the IL-10 levels. The increase in IFN-γ
confirms the immunomodulatory activity of SB-83
because the production of IFN-γ by Th1 lymphocytes
is one of the main activators of macrophages respon-
sible for the control of Leishmania. The SB-83 toxico-
logical study concluded that there were no changes in
biochemical and hematological parameters, suggest-
ing the safety of the compound. The genotoxicity was
analyzed via micronucleus tests, which assesses the
ability of a substance to cause clastogenicity and
aneugenicity. The results showed that SB-83 did not
cause an increase in the number of micronuclei in the
peripheral blood of the treated animals, suggesting
absence of genotoxic effect.
Aguilera et al. evaluated the potential of a new
class of steroids against L. infantum and
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L. amazonensis.[53] The authors synthesized and chemi-
cally characterized a series of nineteen steroidal
arylideneketones and thiazolidenehydrazines and ex-
plored biological activity against L. infantum and
L. amazonensis (both in vitro and in vivo), in addition to
analyzing the genotoxicity and acute toxicity in vitro
and in mice. The data showed that compound 8 (ID
1260, a steroidal thiosemicarbazone compound) (S10)
was most active, with an IC50 of less than 200 nM in
human macrophages infected with L. infantum. In the
genotoxicity test, compound 8 used in a single dose of
150 mg/kg did not induce chromatin damage in bone
marrow cells, thus not presenting toxicity.
Recently, Drugs for Neglected Diseases initiative
(DNDi) reported three classes of lead-derived chem-
icals: benzoxaboroles (S11), aminopyrazoles (S12) and
nitroimidazoles (S13, S14, and S15), which have great
antileishmanial activity. These compounds have shown
favorable pharmacokinetic profiles ensuring bioavail-
ability after oral administration and high levels of
activity against murine visceral leishmaniasis.[54] Van
Bocxlaer et al. evaluated the effectiveness of these
compounds in the in vitro and in vivo models for
cutaneous leishmaniasis.[55] The in vitro activity of the
compounds was evaluated against intracellular amasti-
gote forms of L. major, L. aethiopica, L. amazonensis,
L. panamensis, L. mexicana and L. tropica. Drugs that
demonstrated potent activity (EC50<5 μM) against at
least 4 of 6 species were evaluated in vivo in mouse
models. The animals received treatment for 5 or
10 days with oral or topical formulations. Due to the
cutaneous form of the disease, the efficacy was
expressed by the size of the lesion and the parasitic
load. The results of this study showed that all the
drugs tested showed marked levels of potency against
the species of the Old and New World. In the in vitro
peritoneal assay, the aminopyrazoles showed the most
potent antileishmanial activity with EC50 values in the
nanomolar range (like amphotericin B). It is note-
worthy that 3 nitroimidazoles, 1 benzoxaborole and
3 aminopyrazoles showed consistent and potent activ-
ity against a variety of Leishmania species. Moreover,
all the compounds were well tolerated with no
obvious signs of toxicity observed in mice after oral
administration. In some cases, there was a complete
reduction in the size of the lesion, that was correlated
with the reduction of the parasite load and its
effectiveness was dependent on the dose and duration
of treatment.
Wyllie et al. reported GSK3186899/DDD853651
(S16), a pyrazolopyrimidine derived from trifluoroprop-
yl sulfonamide.[56] This compound was selected as a
preclinical candidate based on the general properties
of the molecule (potency, efficacy in the mouse model,
pharmacokinetics, and safety profile) against VL. In
addition to its favorable physico-chemical and phar-
macokinetic properties, it presented adequate toxico-
logical results for its use in clinical trials. Detailed
studies on the action indicated that the compounds in
this series act mainly by inhibiting the parasite cdc-2
related kinase 12 (CRK12), that is essential in the cell
cycle of the parasite,[57] thus is also a potential
pharmacological target for visceral leishmaniasis.
Treatment with this compound resulted in the accu-
mulation of parasitic cells in the G1 and G2 phases of
the cell cycle together with a decrease in the propor-
tion of cells in the S phase, suggesting a cell cycle
arrest in the G1/S and G2 phases.[56] In another study
carried out by the same research group, the com-
pound GSK3494245/DDD01305143 (S17) (belonging to
the same series), also demonstrated potential to treat
leishmaniasis. The compound was shown to have
promising pharmacokinetic properties and in vivo
efficacy in the mouse model when compared to
miltefosine. Furthermore, it was confirmed that it
worked mainly by inhibiting chymotrypsin-like activity
catalyzed by the β5 subunit of the L. donovani
proteasome.[58]
During a study to discover anti-tuberculosis agents,
Thompson et al. discovered a new class of 7-substi-
tuted oxazines, with potent antileishmanial activity.[59]
After identification and susceptible efficacy tests,
seeking better solubility and safety, the bioisosteres
formed by replacing a phenyl with pyridine or
pyrimidine showed improved solubility and potency,
while more hydrophilic lateral chains reduced the
activity against visceral leishmaniosis. Evaluation of a
representative set of nine racemic compounds in the
visceral leishmaniasis (L. donovani) mouse model
showed phenylpyridines 79 (or R form 71) and 93 (or R
form 94) as the most effective, with compound 93
showing 50% inhibition at 1.56 mg/kg. In the chronic
infection (L. infantum) hamster model, compound 71
(at 12.5 mg/kg) achieved reductions exceeding 99% in
parasite burden for all target organs. Subsequent
synthesis and assessment of the enantiomers of both
lead compounds identified the R forms as superior,
and in the case of 71, this outcome was reinforced by
excellent results in the L. infantum hamster model and
favorable pharmacokinetics data in the hamster and
mouse.
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4. Drug Repurposing
Currently, the need to obtain a drug more quickly and
with lower cost is essential for both the pharmaceut-
ical industry and the population. Thus, the repurposing
of drugs has been gaining space within this market,
allowing reduction in expenses, and at the same time
optimizing the release time by health regulatory
agencies.[60] The reuse of drugs is neither uncommon
nor less profitable for companies and, given the global
health situation, it presents a reliable and safe option
to design an efficient therapy.[61] In the United States,
for example, drug reuse accounted for about 30% of
drug approvals in the recent years.[62] Despite having
some limitations, the reuse of clinical trials represent a
good strategy, because it facilitates the reuse of drugs
already approved, thus reducing the time and
bureaucracy to reach the market.[63] Drug repurposing
helps to develop new therapies with drugs that are
already used clinically and whose tests with patients
are already known.[64]
Using this strategy, Rodrigues et al. demonstrated
that clomipramine (S18) had potential against
L. amazonensis.[65] This medication is a tricyclic anti-
depressant used to treat psychiatric disorders, such as
obsessive-compulsive disorder.[66] In this study, the
parasites were incubated in the presence or absence
of different concentrations of clomipramine for 72 h.
The results demonstrated that the antidepressant was
a selective inhibitor of the extracellular and intra-
cellular forms of the parasite, with IC50 of 8.31�
3.29 μM and IC90 of 21.58�3.44 μM against promasti-
gotes. There was also greater selectivity against para-
sites than host cells, with a selectivity index of 11.72
for amastigotes and 21.81 for promastigotes. Clomipr-
amine has been reported to act via mitochondrial
pathway in L. amazonensis, in addition to inhibiting
the function of the trypanothione reductase.[67] In this
study, Rodrigues et al. showed that both in promasti-
gotes and amastigotes, the drug induced oxidative
stress by increasing the levels of reactive oxygen
species and H2O2.
[65] In promastigotes, the reduction
in cell size, membrane shrinkage, DNA fragmentation
and exposure to phosphatidylserine, suggests cell
death via apoptosis. Despite changes in mitochondrial
physiology, ATP levels were not affected in promasti-
gotes and amastigotes, and no loss of membrane
integrity was observed.
Bemani et al. evaluated amiodarone (S19) (a antiar-
rhythmic class III drug) against L. major.[68] The authors
reported good potential in both in vitro and in vivo
analyzes, through tests related to wound healing,
immune response, activities of antioxidant enzymes
and malondialdehyde (MDA), ferric reducing ability of
plasma (FRAP) and adiponectin levels in infected mice.
An IC50 of 1 μM (promastigotes) and 0.7 μM (amasti-
gotes) was observed. There was a decrease in the size
of lesions treated with amiodarone (40 mg/kg) after
12 days. The number of macrophages and neutrophils
were lower in the lesions of animals treated with the
drug, so that they demonstrated adequate formation
of granulation tissue, well vascularized and infiltrated
by fibroblasts and mature fibrocytes, different from
untreated groups that presented necrosis, infiltration
by polymorphonuclear cells, macrophages, and lym-
phocytes, as well as small amounts of fibrous con-
nective tissue with few newly regenerated blood
vessels. Greater angiogenesis was observed in lesions
treated with amiodarone, probably due to the
decrease of levels of tumor necrosis factor-α (TNF-α)
and interleukin cytokines such as IL-6. Although the
presence of TNF-α has an advantage over the host’s
defense mechanism against pathogens, an excessive
release results in impaired healing. Moreover, it is
necessary to have a balance in the release of IL-6, since
this interleukin mediates the transition from acute to
chronic inflammation. Despite the potential of amio-
darone, total wound healing was not observed. The
parasitic load decreased after 28 days of treatment.
There was no significant increase in adiponectin and
MDA, important in the wound healing process.
Amiodarone caused the formation of autophago-
somes, and the presence of lipid bodies and vacuoles
in the cytoplasm could be observed. However, the
long duration or the administration of high doses of
amiodarone have been reported to cause toxicity in
several organs.[69–73]
Morais-Teixeira et al. evaluated fexinidazole (S20)
in vitro and in vivo studies against L. infantum, L. ama-
zonensis, L. braziliensis and L. guyanensis.[74] Fexinida-
zole is a nitroimidazole that was developed in the
1980s against trypanosomes. The authors observed
that after 23 days of oral treatment with fexinidazole
(200 and 300 mg/kg/day), 80% of the animals infected
with L. amazonensis presented complete healing of
the lesion. On the other hand, 100% of the animals
infected with L. guyanensis and treated orally with
fexinidazole (200 mg/kg/day) presented a completely
healed lesion with 98.4% reduction in the alterations
observed in the liver and no significant loss of animal
body weight. Fexinidazole thus presented good
potential without toxicity in spite of high doses
required for the treatment in the animal model.
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5. Clinical Trials
Leishmaniasis is an important neglected tropical
disease, despite it being one of the six most frequent
parasitic diseases in the world. Very few advances
have been made for its treatment, with the same
pharmacological treatments in use since 1940s. The
drugs currently in use for the treatment are associated
with low therapeutic indices and significant side
effects.[75] Thus, the search for more effective therapies
that present fewer side effects for the treatment of
leishmaniasis is necessary.
Vast majority of clinical studies in process involve
improving the efficacy of drugs already in use for the
treatment of leishmaniasis such as pentavalent anti-
monials (sodium sybogluconate and meglumine anti-
moniate), amphotericin B deoxycholate, lipid formula-
tions of amphotericin B (e.g., AmBisome@, ABLC,
Amphocil@), miltefosine, paromycin and
pentamidine,[76] and are related, more specifically, to
improve the dose regimen. There are very few
potential new drugs in the clinical phase for the
treatment of leishmaniasis.
Four drugs (DNDI-0690, DNDI-6148, LXE408 and
GSK3494245) in which preclinical development has
already been completed have started the clinical
studies since 2019. DNDI-0690 belongs to the class of
nitroimidazole (a class known for its broad spectrum
of antiparasitic properties) which was developed from
fexinidazole (structural improvement).[77,78] The pre-
clinical development of DNDI-0690 (S13) has already
been completed after observing that it is highly
effective in mice and hamsters VL models.[79,80] Its nitro
group is believed to be bioactivated by the enzyme
nitroreductase NTR2 in Leishmania parasites,[81] leading
to reactive intermediates that kill the parasite. Under
the title “Single Oral Dose Escalation Study of DNDI-
0690 in Healthy Subjects”, the project was approved
for the phase I clinical studies (NIH, 2019; identifying
number: NCT03929016).
Another drug in clinical trial for the treatment of
Leishmania is DNDI-6148 (S11) belonging to the class
of oxaborole. It was observed that after 5 to 10 days of
treatment, this drug could reduce high levels of
parasitic load in VL mice and hamster models. Its
mechanism of action is not yet well understood, but it
is thought to be distinct from the antileishmanial
therapies currently used, since it maintains activity
against strains resistant to these drugs. The pharmaco-
logical safety studies for this drug have already been
completed.[80,82,83] DNDI-6148 was approved at the
end of 2018 for phase I clinical studies, with the
objective to evaluate its safety and tolerance in
increasing single doses (10 mg, 20 mg, 40 mg, 80 mg,
160 mg, 260 mg, 380 mg, and 500 mg) in healthy male
volunteers compared to the placebo group. In addi-
tion, the phase I study is also being used to study the
pharmacokinetic and pharmacodynamic properties of
DNDI-6148.[84]
Nagle et al. showed that the chemical optimization
of GNF6702 successfully led to the compound LXE408
(S21) which, when administered orally, demonstrated
excellent efficacy in mice model with a good safety
profile.[85] Based on these positive results, LXE408 was
approved for clinical trials. In February 2020, the
Novartis pharmaceutical industry and the Drugs for
Neglected Diseases initiative (DNDi), a non-profit re-
search and development (R&D) organization signed a
collaboration and license agreement to jointly develop
the LXE408. In this agreement, Novartis was respon-
sible for completing phase I clinical trials. While DNDi
was responsible for Phase II and Phase III trials, with
the first Phase II study scheduled to begin in early
2021 in India, with additional testing planned to take
place in East Africa.[86]
GSK3494245 (S17), which was initially identified as
a proteasome inhibitor, is a candidate for the treat-
ment of leishmaniasis due to its potential preclinical
leishmanicidal effect, in addition to demonstrating a
desirable safety profile and pharmacokinetics.[87] The
phase I clinical study titled “Safety, Tolerability and
Pharmacokinetics Investigation of GSK3494245 in
Healthy Participants” began in September 2020 is
a randomized, double-blind, placebo-controlled study
to evaluate in humans the safety, tolerability and
pharmacokinetics of single doses of GSK3494245 in
healthy participants, and consists of 3 cohorts (co-
horts 1, 2 and 3), conducted in sequential order.[88]
Table 1 summarizes the novel molecules described in
this study. Despite efforts, the number of drugs
reaching human trials is still extremely low.
6. Future Perspectives
Currently, there is no fully effective therapy for
leishmaniasis. Treatment is based on chemotherapy;
however, most drugs are expensive and have toxic
side effects. Although advances are limited, the
scientific community has been searching for new
strategies and compounds that have little or no toxic
effect in relation to the current treatment, such as the
use of immunotherapies, nanoparticles, vaccines, and
substances for topical use (Figure 4). The development
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process normally occurs through the Target Product
Profile, a planning tool that describes the result of
research and development of desired drugs and allows
the selection, progression, and management according
to well-defined decision matrices. Accordingly, some
parameters are defined for the choice of the Pre-
clinical Target Candidate Profile, in which the physico-
chemical, pharmacokinetic, safety and formulation
properties of the selected compound are described for
pre-clinical development, functioning as a prologue
for clinical studies.
Studies have highlighted the use of nanoparticles
to reduce drug resistance. The use of drug liberation
systems based on nanotechnology, loaded with anti-
leishmania agents, can protect the drugs against
oxidation reduction and enzymatic reactions, increase
bioavailability through controlled drug release and
increase efficacy. The scientific community has also
investigated the drug-immunotherapy relationship to
optimize the treatment of leishmaniasis. Despite
promising results, this treatment cannot be recom-
mended due to its high cost. Topical therapies have
proven to be less toxic option compared to systemic
options, however, limited to less severe forms of
treatment, without the risk of dissemination and
development of the disease. These methods are
recommended for individuals with few and small
injuries, more effective in infections by L. mexicana or
L. major. Synergistic drug combinations are another
option for a more effective treatment, as combinatorial
therapies are also relatively cheaper and present a
minimal risk to patients due to the access to previous
Table 1. Recent pre-clinical and clinical studies, described for leishmaniasis.
Drug Tested Species Study Phase Refs.
Thiazopyridine (TP)
Thiazoacetylpyridine (TAP)
L. infantum Pre-clinical (in vitro) [26]
trans-dibenzalacetone (DBA) L. infantum
L. amazonensis
L. chagasi
Pre-clinical (in vitro) [27]
Imiquimod L. tropica
L. major
Pre-clinical (in vitro) [89]
Ursolic acid (UA) L. amazonensis
L. infantum
Pre-clinical (in vivo) [40]
Chloroquinoline derivative (GF1059) L. infantum
L. amazonensis
Pre-clinical (in vivo) [43]
Ruthenium nitrosyl complex (RuNO) L. brasiliensis Pre-clinical (in vitro and in vivo) [41]














Pre-clinical (in vitro and in vivo) [80]





Pre-clinical (in vitro) [59]
Clomipramine L. amazonensis Pre-clinical (in vivo) [51]





Pre-clinical (in vitro and in vivo) [74]
DNDI-0690 L. mexicana
L. major
Phase 1 clinical trials [80]
DNDI-6148 L. major
L. donovani
Phase 1 clinical trials [84]
LXE408 L. donovani Phase 1 has been completed [85]
GSK3494245 L. donovani Phase 1 clinical trials [87]
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pharmacological, safety and toxicological data. Vac-
cines have shown excellent results, especially in
prevention, however, they are not widely researched
and developed. It is believed that its commercializa-
tion is less lucrative, when compared to the develop-
ment of drugs, making research inclined to immuno-
therapeutic formulations. It is also worth to mention
that, due to the complexity of the immune responses
necessary for protection against Leishmania, the devel-
opment of vaccines has been a challenging task.
Finally, the control of this disease is done exclusively
with medications and follows the therapeutic protocol
of each country, respecting its regionality and the
guidelines of the World Health Organization. The
scarcity of new anti-leishmania agents highlights the
need to search for newer molecules with anti-
leishmania activity, mainly due to the emergence of
strains resistant, complications created due to co-
infections and toxicity shown by the conventional
drugs. Thus, although there have been countless
advances, treatment against leishmaniasis is still
considered a challenge and the search for ideal
treatments continue.
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